



PRODUCT: Moxidectin

COMPANY: Medicines Development for Global Health & TDR

THERAPEUTIC AREA & INDICATION:

New treatment for onchocerciasis (river blindness) demonstrating superiority over ivermectin, the current standard of care against this major neglected infectious disease prevalent in developing countries

ABOUT THE PRODUCT

Moxidectin is an endectocide approved by the US FDA in 2018 for treatment of the neglected tropical disease onchocerciasis, also known as “river blindness”. In pivotal studies, moxidectin was superior to ivermectin, becoming the first advance for this disease in 30 years. Medicines Development for Global Health who licensed moxidectin from WHO TDR in 2014, is now undertaking further development to support inclusion of moxidectin in WHO Treatment Guidelines with the goal of accelerating elimination of this devastating disease. Moxidectin is also being clinically evaluated as a potential therapy for scabies, lymphatic filariasis and the soil-transmitted helminths.